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The systematic review by Savaris and colleagues1 in this issue of Sexually Transmitted Infections is 
important for two reasons. First, the review of the treatment of pelvic inflammatory disease (PID), a 
common condition for which the management is contentious, driven by traditions and not 
necessarily evidence-based. Second, the publication of this abridged review will help to strengthen 
links between the Sexually Transmitted Infections Cochrane Review (STICRG, 
https://sti.cochrane.org/)3 and the journal Sexually Transmitted Infections to bring important clinical 
evidence from the Cochrane Library closer to our readers and other practitioners.  
The systematic review of antibiotic therapy for PID, which included 37 randomised controlled trials, 
makes for interesting reading, particularly about the use of nitroimidazoles.1 The evidence suggests 
that the addition of metronidazole to any of the evaluated regimens does not improve clinical cure 
for either mild to moderate PID (five trials, 1383 women) or severe PID (11 trials, 2427 women).1 The 
authors judged the quality of the evidence as moderate rather than high, presumably because of 
missing information from the trial reports (Figures 1 and 2 in the published paper). The authors 
suggest that other antibiotics in the regimens tested must have provided enough anaerobic cover. 
Metronidazole is widely recommended to treat vaginal anaerobic bacteria that are often found in 
women with PID, but whose role in upper genital tract infection is still not proven.4 Regimens that do 
not contain metronidazole could reduce adherence to antibiotic regimens and reduce concern about 
antimicrobial resistance, given that nitroimidazoles are the only class of drug recommended for 
treatment of Trichomonas vaginalis. Clinical guideline developers should take these findings into 
consideration. But a quick look at the 2018 British Association for Sexual Health and HIV guideline 
for the management of PID shows that the review evidence hasn’t filtered through. The guideline 
gives the highest (grade 1A) recommendation for outpatient and inpatient regimens containing 
metronidazole.5 The search for the systematic review ended in July 2016, so new trials with 
improved reporting of results might provide more certainty when the authors update the Cochrane 
Review in 2020. 
The Cochrane Collaboration benefits from the co-publication of systematic reviews in journals like 
ours because the abridged version reaches a wider audience that includes the end users. Cochrane 
Collaboration systematic reviews must adhere to high standards of completeness, methods to 
reduce the risk of bias, transparency and reporting. These requirements can make the full review 
very long and difficult to understand for people who are not familiar with their structure and 
language. An abridged review can highlight the most salient findings from a review and put them 
into context for a specific audience. The full Cochrane Library review provides all the details, 
although access is restricted to those with subscriptions or exemptions. Guideline development 
  3 
 
groups should identify and make use of the full Cochrane review, but an abridged version can also 
draw attention to topics that are of current relevance to clinical practice.  
Sexually Transmitted Infections will consider future co-publication of reviews from the STICRG and 
other relevant Cochrane review groups. The Box gives some tips for authors who want to co-publish 
a Cochrane review, based on the Cochrane Community’s editorial and publishing policy2 and our 
experience in editing this submission. In the meantime, the STICRG encourages clinicians and 
researchers to get involved in the STICRG. The STICRG editorial office is at the National University of 
Colombia, Bogotà, Colombia and the group is a satellite of the Cochrane Gynaecology and Fertility 
Group. Look out for Cochrane Collaboration training courses (https://training.cochrane.org/) online, 
webinars, workshops and long courses and get in touch with our managing editor, Olga Gomez 
(cochranestieditorialoffice@gmail.com), who can put you in touch with review authors. Help to 
make sure that the management of sexually transmitted infections is based on the best possible 
evidence.  
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Box: Co-publication of a Cochrane Review in Sexually Transmitted Infections  
 
1) Authors of a Cochrane Review who want to publish an abridged version should read the 
Cochrane Community policy2 on co-publication. 
2) The BMJ Publishing Group has an agreement with the Cochrane Library to co-publish 
Cochrane Reviews and authors need to complete a ‘Permission to co-publish’ form.  
3) An abridged Cochrane Review will not be considered as a duplicate or redundant publication 
if it is consistent with guidance from the International Committee of Medical Journal Editors 
regulations on secondary publication (http://www.icmje.org/icmje-recommendations.pdf), 
which include clear citation and acknowledgment of the Cochrane Review.  
4) The abridged version needs to be a standalone article. Readers need to be able to read and 
understand the abridged version without reference to the full Cochrane review. Authors 
should explain what they are reporting in the abridged version and what additional 
information can be found in the Cochrane Review. All information about included studies and 
data used for analysis need to be available in the abridged version.  
5) An abridged Cochrane Review will undergo the full editorial process, including peer review, 
following submission to Sexually Transmitted Infections. Submission of an abridged Cochrane 
Review does not guarantee acceptance.  
6) If invited to revise their manuscript, authors need to take into account the peer reviewers’ 
suggestions. If appropriate, the authors should take these changes into account when they 
update their Cochrane Review. 
7) If changes to the manuscript result in differences in the results or the conclusions of the 
systematic review, the authors must discuss the changes with the STICRG.  
